Fixed-Duration Ibrutinib–Venetoclax vs Chlorambucil–Obinutuzumab for Previously Untreated CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol 2023 Nov 06;[EPub Ahead of Print], CU Niemann, T Munir, C Moreno, C Owen, GA Follows, O Benjamini, A Janssens, MD Levin, T Robak, M Simkovic, S Voloshin, V Vorobyev, M Yagci, L Ysebaert, K Qi, Q Qi, P Sinet, L Parisi, S Srinivasan, N Schuier, K Baeten, A Howes, DB Caces, AP KaterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.